What are ACSL4 antibodies?
Anti-ACSL4 antibodies are immunoglobulins that specifically recognize and bind ACSL4, the gene encoding long-chain-fatty-acid--CoA ligase 4 (also known as FACL4) in humans. In research applications, these antibodies are used to detect ACSL4 in tissue samples, cell lysates, and cultured cells. ACSL4 catalyzes the conversion of long-chain fatty acids, preferentially arachidonate and eicosapentaenoate, to their active acyl-CoA form for use in lipid synthesis and beta-oxidation. Because ACSL4 shapes the polyunsaturated fatty acid content of membrane phospholipids, it is a widely used marker and driver of ferroptosis in cancer research.
Catalog highlights and purchasing considerations
About the Biocompare ACSL4 antibody catalog
The Biocompare antibody search tool lists anti-ACSL4 antibodies from a range of suppliers, spanning unconjugated and fluorophore- or enzyme-conjugated formats. Listings may also appear under the alternate name FACL4. Western blot is the most common validated application among these listings, followed by immunohistochemistry and immunofluorescence. Several ACSL4 antibodies mentioned here have been cited across a range of ferroptosis research, including ferroptosis regulation in breast cancer through m5C RNA methylation, ferroptosis induction in hepatocellular carcinoma via chaperone-mediated autophagy, and ferroptosis-driven retinal pigment epithelial cell injury in diabetic retinopathy.
Considerations when choosing an ACSL4 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.